Eli Lilly to Acquire Adverum Biotechnologies in $1.5 Billion Deal to Advance Gene Therapy for Vision…
Eli Lilly and Company announced it will acquire Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage biotechnology company pioneering intravitreal gene therapies for eye…
Read More...
Read More...
